Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.

scientist in lab

In the trial, which recruited over 32,000 volunteers across all age groups, the participants received either two standard doses of the Oxford-AstraZeneca vaccine or a placebo vaccine, at a four-week interval. These data show that the vaccine is 79% effective against symptomatic COVID-19, and 100% effective against severe, or critical symptomatic COVID-19. 

These results also add to the extensive safety data collected both in previous trials and through real-world vaccine roll out schemes. The independent Data and Safety Monitoring Board (DSMB) reported no safety concerns among the participants receiving at least one dose of the vaccine.  

The absolute efficacy is higher in this new study than observed in the Oxford-led studies, as efficacy is affected by the protocol case definition (higher for more severe cases) and the population in which the study is conducted. Today’s findings are in line with findings from other major vaccine developers who studied efficacy in the US. 

Andrew Pollard, Professor of Paediatric Infection and Immunity, and Lead Investigator of the Oxford University trial of the vaccine, said: 

These results are great news as they show the remarkable efficacy of the vaccine in a new population and are consistent with the results from Oxford-led trials. We can expect strong impact against COVID-19 across all ages and for people of all different backgrounds from widespread use of the vaccine.  

Sarah Gilbert, Professor of Vaccinology, and co-designer of the ChAdOx1 nCov-19 coronavirus vaccine, said: 

‘These new results from the large phase III trials in the US, Chile and Peru provide further confirmation of the safety and effectiveness of ChAdOx1 nCoV-19. In many different countries and across age groups, the vaccine is providing a high level of protection against COVID-19 and we hope this will lead to even more widespread use of the vaccine in the global attempts to bring the pandemic to an end.’ 

AstraZeneca will be submitting the data for analysis by the scientific community in peer-review literature, and to the regulators in the USA, the US Food and Drugs Administration (FDA) and for emergency approval for use.

Similar stories

Benemérita Universidad Autónoma de Puebla representatives visit Jenner Institute

Academic representatives from Benemérita Universidad Autónoma de Puebla (BUAP), one of the leading universities in Mexico, paid a visit to NDM’s Jenner Institute.

RECOVERY trial team wins the MRC Impact Prize

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Continued support to CPM helps it explore personalised medicine

The Dr Stanley Ho Medical Development Foundation will continue its funding support for The Centre for Personalised Medicine (CPM) for further seven years.

Shifting the needle: finding solutions for rare diseases

Rare diseases are a global health challenge. To address this, organisations around the world, including the Nuffield Department of Medicine (NDM), are working together to find solutions for patients.

Coronavirus Vaccines Research and Development Roadmap launched

The Coronavirus Vaccines Research and Development Roadmap is a comprehensive plan to galvanize a global effort to protect the world from this large and dangerous family of viruses.

Lithuanian Ambassador visits the Ludwig Institute for Cancer Research

The Lithuanian Ambassador to the United Kingdom, His Excellency Mr Eitvydas Bajarūnas, paid a visit to Professor Skirmantas Kriaučionis of the Ludwig Institute for Cancer Research at the Nuffield Department of Medicine.